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Purpose
To evaluate the influence of HIV-1 tropism on virologic
and immunologic responses in antiretroviral-naïve HIV-
1-infected patients enrolled in the ArTEN trial (atazana-
vir/r vs. nevirapine along with tenofovir/emtricitabine).
Methods
Baseline plasma samples from patients enrolled in the
ArTEN trial were tested genotypically for HIV tropism
using geno2pheno (5.75% FPR) and PSSM (enhanced for
X4 detection; Poveda et al, JAC 2009). Univariate and
multivariate analyses were performed to find variables
associated with virologic/immunological outcome. Para-
meters examined included gender, Hepatitis coinfection,
HIV subtype, treatment arm, viral tropism, baseline
CD4 counts and VL.
Results
428 out of 569 randomized and treated patients could
be analyzed, 146 on ATZ/r and 282 on NVP. Overall,
332 (76.9%) subjects were infected with subtype B var-
iants and 45 (10.4%) were HCV coinfected. The V3
successful amplification rate was 92.1% (394/428). X4
variants were found in 14% (55/394) by geno2pheno
and 29.2% (115/394) by PSSM, with no significant dif-
ferences between treatment arms or HIV clade. See
Table 1.
At baseline, patients with X4 viruses by geno2pheno
had higher VL (5.4 [IQR:5-5.7] vs. 5.2 [4.7-5.6] log
copies/mL, p=0.044) and lower CD4 counts (145 [62-
200] vs. 188 [134-260] cells/mm3, p<0.001) than those
with R5 viruses. At weeks 24 and 48, the proportion of
patients with VL <50 copies/mL was similar in both
treatment arms, but lower in those with X4 than R5
viruses. The multivariate analysis confirmed HIV trop-
ism as independent predictor of virologic response at
week 24, along with baseline VL and CD4 count. In
contrast, the extent of CD4 gains was not significantly
determined by HIV tropism, but it was by baseline VL,
CD4 count and treatment arm.
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Table 1
Endpoint HIV tropism (g2p) Treatment arm
R5 X4 p(uni) p(multi) ATZ/r NVP p(uni) p(multi)
Week 24
% of patients with VL<50 copies/mL 83.2 60.9 0.001 0.012 77.2 82.1 0.281 0.384
CD4 gain (cells/mm
3) 116[56-197] 117[66-172] 0.979 0.439 116[72-203] 111[45-111] 0.316 0.173
Week 48
% of patients with VL<50 copies/mL 91.6 76.9 0.009 0.061 88.5 92.0 0.340 0.434
CD4 gain (cells/mm
3) 156[83-244] 180[86-235] 0.729 0.616 180[99-251] 152[78-230] 0.037 0.008
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HIV-1 tropism is an independent predictor of virologic
response at week 24 in ARV-naïve patients treated with
NVP or ATZ/r plus TDF/FTC. In contrast, CD4 gains
are not determined by viral tropism. This observation
may have important clinical implications, as it may be
worthwhile testing for viral tropism, besides VL, CD4
counts and resistance before beginning any HAART
regimen.
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